

Dear Fabry community leader,

We recently announced disappointing [news](#) about our Phase 2 FAB-GT gene therapy clinical development program for Fabry disease, which showed variable cell engraftment, a key indicator of efficacy, among the five most recently dosed patients. It's important to note that this was not a safety issue. Unfortunately, these new data, as well as an increasingly challenging market and regulatory environment for Fabry disease, have caused us to deprioritize our Fabry program. We are working to better understand these data and intend to publish any relevant findings in the future.

While this has been a difficult decision, we believe this is the right step forward for AVROBIO and preserves our ability to continue developing therapies for the lysosomal disorder community. It is our commitment to continue to develop only the highest quality treatments for those living with rare diseases, and we continue to strive toward creating a world free of these genetic diseases.

We are grateful for all the participants in our clinical trials and recognize the important contribution they have made to advancing the science of gene therapy. We share in their disappointment that the outcome was not what we would have hoped, and we are optimistic that the community maintains its dedication to research so other efforts underway can potentially find solutions to address unmet needs in Fabry disease.

We are working with investigators and institutional review boards (IRBs) regarding next steps for the current trial participants. Even though we are no longer enrolling new participants into the FAB-GT clinical trial, we are preparing to follow participants in a 14-year long-term follow up study to continue to monitor safety and efficacy of the gene therapy.

We will continue to support the Fabry disease community, and we commit to working with community leaders to navigate this transition and, as appropriate, share our learnings with the research, physician and patient communities. To connect with us, please reach out to [patientadvocacy@avrobio.com](mailto:patientadvocacy@avrobio.com).

Thank you for all the insights you provided to us and everything you do for the Fabry community.

Sincerely,  
Geoff MacKay  
President & CEO

